August 2018 Br J Cardiol 2018;25:90–1
Christopher Allen
Coronary intervention – Trials As the first ever blinded, sham-controlled, percutaneous coronary intervention (PCI) trial, demonstrating a non-statistically significant increase in exercise time at six weeks from PCI over optimal medical therapy (OMT), to say the publication of ORBITA (Percutaneous Coronary Intervention in Stable Angina) last year caused a stir would be quite the understatement. Regardless of your interpretation of the data,1 or ensuing hyperbole,2 unanswered questions certainly remained. Presentation of the previously blinded, invasive physiology data in the opening late-breaking clinical trials session here was therefore
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits